Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Consolidated Net Income (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Consolidated Net Income data on record, last reported at -$97.0 million in Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 323.7% year-over-year to -$97.0 million; the TTM value through Dec 2025 reached -$23.4 million, down 114.12%, while the annual FY2025 figure was -$5.3 million, 103.22% down from the prior year.
  • Consolidated Net Income reached -$97.0 million in Q4 2025 per AMPH's latest filing, down from $17.3 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $49.6 million in Q3 2023 and bottomed at -$97.0 million in Q4 2025.
  • Average Consolidated Net Income over 5 years is $22.3 million, with a median of $26.6 million recorded in 2023.
  • Peak YoY movement for Consolidated Net Income: skyrocketed 703.36% in 2021, then crashed 323.7% in 2025.
  • A 5-year view of Consolidated Net Income shows it stood at $20.0 million in 2021, then surged by 126.03% to $45.1 million in 2022, then decreased by 26.05% to $33.4 million in 2023, then rose by 29.96% to $43.4 million in 2024, then tumbled by 323.7% to -$97.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Consolidated Net Income were -$97.0 million in Q4 2025, $17.3 million in Q3 2025, and $31.0 million in Q2 2025.